Finance

Lists
RVTY:NYSE
Revvity Inc
$114.66
+0.37%
(+0.42) 1D
$114.66
0.00% (0.00)
After hours
Closed: Aug 7, 4:00:03 PM GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for RVTY...
Open
$114.98
High
$115.51
Low
$113.74
Mkt. cap
12.79B
Avg. vol.
1.61M
Volume
1.03M
52-wk high
$118.30
52-wk low
$81.22
Beta
1.07
Shares outstanding
111.56M
No. of employees
11K
Open
$114.98
High
$115.51
Low
$113.74
Mkt. cap
12.79B
Avg. vol.
1.61M
Volume
1.03M
52-wk high
$118.30
52-wk low
$81.22
Beta
1.07
Shares outstanding
111.56M
No. of employees
11K
News stories
From sources across the web
Yahoo Finance
Yahoo Finance
·
15 hours ago
Revvity Q2 Earnings Call Highlights
Profile
Revvity, Inc. is a multinational company headquartered in Waltham, Massachusetts, USA, in the life sciences and diagnostics business that is focused on selling to the pharmaceutical and biotechnology industries, especially in relation to approaches making use of new cell therapy or gene therapy developments. Its origins lie with the long-existing company PerkinElmer, which has been in a variety of business lines. In 2022, a split of PerkinElmer resulted in one part, comprising its applied, food and enterprise services businesses, being sold to the private equity firm New Mountain Capital for $2.45 billion and thus no longer being public but keeping the PerkinElmer name. The other part, comprising the life sciences and diagnostics businesses, remained public but required a new name, which in 2023 was announced as Revvity, Inc. From the perspective of Revvity, the goal of creating a separate company was that its businesses might show greater profit margins and more in the way of growth potential. An associated goal was to have more financial flexibility moving forward. On May 16, 2023, the PerkinElmer stock symbol PKI was replaced by the new symbol RVTY. Wikipedia
About Revvity Inc
CEOPrahlad Singh
Employees11K
Founded1947
HeadquartersWaltham, Massachusetts, United States
SectorHealth care
Analyst ratings
Based on 11 analysts giving stock ratings to RVTY in the past 3 months
Buy
Buy
3
Hold
8
Sell
0
12-month forecast
Based on 11 Wall Street analysts offering 12 month price targets for RVTY in the last 3 months.
Highest
Current $114.66
$130.00 (+13.38%)
Average
$115.14 (+0.42%)
Lowest
$105.00 (-8.42%)
Analyst
Recommendation
Action
Price target
Projected
Date
Casey Woodring
J.P. Morgan
Hold
Maintained
$110.00
-4.1%
08/06/2026
Vijay Kumar
Evercore ISI
Buy
Maintained
$126.00
+9.9%
08/05/2026
Unknown Analyst
Wells Fargo
Hold
Maintained
$110.00
-4.1%
08/05/2026
Daniel Arias
Stifel Nicolaus
Hold
Reiterated
$110.00
-4.1%
08/05/2026
Daniel Brennan
TD Cowen
Buy
Reiterated
$130.00
+13.4%
08/07/2026
Eve Burstein
Bernstein
Hold
Maintained
$115.00
+0.3%
07/22/2026
Puneet Souda
Leerink Partners
Buy
Reiterated
-
-
07/17/2026
Luke Sergott
Barclays
Hold
Maintained
$105.00
-8.4%
06/24/2026
Michael Polark
Wolfe Research
Hold
Initiated
-
-
06/01/2026
Michael Ryskin
Bank of America Securities
Hold
Maintained
-
-
05/14/2026
Unknown Analyst
Guggenheim
Hold
Reiterated
-
-
05/11/2026
Evie Koslosky
Goldman Sachs
Hold
Maintained
$100.00
-12.8%
05/06/2026
Catherine Ramsey Schulte
Robert W. Baird
Buy
Maintained
$117.00
+2%
05/04/2026
Unknown Analyst
Goldman Sachs
Hold
Maintained
$95.00
-17.1%
04/14/2026
Jack Meehan
Nephron
Hold
Upgraded
$90.00
-21.5%
03/26/2026
Unknown Analyst
UBS
Buy
Maintained
$120.00
+4.7%
02/03/2026
Brandon Couillard
Wells Fargo
Hold
Maintained
$110.00
-4.1%
02/03/2026
Tycho Peterson
Jefferies
Hold
Maintained
$105.00
-8.4%
02/02/2026
Last report
Aug 4, 2026
Fiscal period
Q2 2026
EPS / Est. (USD)
$1.41 / $1.22
+15.93%beat
Revenue / Est. (USD)
729.69M / 702.97M
+3.80%beat
Fiscal Q2 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in USD
Sep 2025
Dec 2025
Apr 2026
Jul 2026
Revenue
698.95M
772.06M
711.12M
729.69M
Cost of goods sold
324.34M
350.40M
323.46M
312.82M
Cost of revenue
324.34M
350.40M
323.46M
312.82M
Research and development expenses
50.80M
58.18M
57.89M
48.97M
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
227.44M
208.55M
241.91M
243.62M
Operating expense
278.23M
266.73M
299.80M
292.59M
Total operating expenses
602.58M
617.12M
623.26M
605.42M
Operating income
96.37M
154.93M
87.86M
124.27M
Other non operating income
-
-
-
-2.80M
EBT including unusual items
55.68M
91.56M
49.99M
63.53M
EBT excluding unusual items
76.49M
133.38M
65.92M
103.74M
Income tax expense
8.46M
-4.21M
9.10M
10.05M
Effective tax rate
15.20%
-4.60%
18.20%
15.82%
Other operating expenses
-
-
-
-
Net income
46.65M
98.36M
40.72M
51.82M
Net profit margin
6.67%
12.74%
5.73%
7.10%
Earnings per share
1.18
1.70
1.06
1.41
Interest and investment income
6.92M
5.75M
6.30M
5.26M
Interest expense
-22.77M
-23.51M
-24.72M
-22.99M
Net interest expenses
-15.85M
-17.76M
-18.41M
-17.73M
Depreciation and amortization charges
-
-
-
-
EBITDA
198.43M
258.01M
192.91M
226.31M
Gain or loss from assets sale
-
-
-5.07M
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more

Research

What's on your mind?
What's going on with the markets today?
Explore what’s possible
Create a portfolio
Create a task
Deep Search
AI content may include mistakes. Learn more
Google apps